In cancer contexts such as colorectal cancer where upregulated WNT/β-catenin is mediated by constitutively activating downstream mutations in CTNNB1 or APC, therapeutic approaches to modulating WNT/β-catenin signalling have been somewhat limited. The gene discussed is CTNNB1; the disease is cancer.